S&P 500   3,923.68
DOW   31,490.07
QQQ   291.14
S&P 500   3,923.68
DOW   31,490.07
QQQ   291.14
S&P 500   3,923.68
DOW   31,490.07
QQQ   291.14
S&P 500   3,923.68
DOW   31,490.07
QQQ   291.14
NASDAQ:WINT

Windtree Therapeutics (WINT) Stock Forecast, Price & News

$0.56
-0.02 (-3.45%)
(As of 05/18/2022 04:00 PM ET)
Add
Compare
Today's Range
$0.54
$0.62
50-Day Range
$0.52
$1.16
52-Week Range
$0.48
$3.40
Volume
214,033 shs
Average Volume
541,391 shs
Market Capitalization
$16.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.29
30 days | 90 days | 365 days | Advanced Chart
Receive WINT News and Ratings via Email

Sign-up to receive the latest news and ratings for Windtree Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Windtree Therapeutics logo

About Windtree Therapeutics

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:WINT
Employees
31
Year Founded
N/A

Sales & Book Value

Annual Sales
$200 thousand
Book Value
$1.48 per share

Profitability

Net Income
$-67.64 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
24,492,000
Market Cap
$16.44 million
Optionable
Not Optionable

Company Calendar

Last Earnings
3/31/2022
Today
5/19/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.45 out of 5 stars

Medical Sector

179th out of 1,418 stocks

Biological Products, Except Diagnostic Industry

24th out of 210 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -













Windtree Therapeutics (NASDAQ:WINT) Frequently Asked Questions

Is Windtree Therapeutics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Windtree Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Windtree Therapeutics stock.
View analyst ratings for Windtree Therapeutics
or view top-rated stocks.

Are investors shorting Windtree Therapeutics?

Windtree Therapeutics saw a increase in short interest in April. As of April 30th, there was short interest totaling 888,700 shares, an increase of 104.6% from the April 15th total of 434,400 shares. Based on an average trading volume of 706,300 shares, the days-to-cover ratio is currently 1.3 days. Currently, 5.3% of the company's shares are short sold.
View Windtree Therapeutics' Short Interest
.

When is Windtree Therapeutics' next earnings date?

Windtree Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Windtree Therapeutics
.

How were Windtree Therapeutics' earnings last quarter?

Windtree Therapeutics, Inc. (NASDAQ:WINT) released its quarterly earnings data on Thursday, March, 31st. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.33) by $0.13.
View Windtree Therapeutics' earnings history
.

When did Windtree Therapeutics' stock split? How did Windtree Therapeutics' stock split work?

Windtree Therapeutics shares reverse split before market open on Wednesday, April 29th 2020. The 1-3 reverse split was announced on Tuesday, April 28th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 28th 2020. An investor that had 100 shares of Windtree Therapeutics stock prior to the reverse split would have 33 shares after the split.

What price target have analysts set for WINT?

1 brokers have issued 12 month price objectives for Windtree Therapeutics' shares. Their forecasts range from $8.00 to $8.00. On average, they anticipate Windtree Therapeutics' stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 1,331.1% from the stock's current price.
View analysts' price targets for Windtree Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Windtree Therapeutics' key executives?
Windtree Therapeutics' management team includes the following people:
  • Mr. Craig E. Fraser, Pres, CEO & Director (Age 57, Pay $769.96k) (LinkedIn Profile)
  • Mr. John P. Hamill, Sr. VP, CFO & Corp. Sec. (Age 58, Pay $463.55k)
  • Mr. Eric L. Curtis M.B.A., Sr. VP & COO (Age 53, Pay $526.25k)
  • Mr. George Cox, VP of Technical Operations (Age 70)
  • Ms. Diane Carman Esq., SVP & Gen. Counsel
  • Dr. Steven G. Simonson, Sr. VP & Chief Medical Officer (Age 63)
  • Dr. Pratap Paruchuru, Exec. Director of Clinical Devel.
  • Ms. Tracy Rarick, Head of Operations & Program Management
  • Dr. Ronald L. Dundore, Exec. Director of Regulatory Affairs & Quality (Age 67)
What is Windtree Therapeutics' stock symbol?

Windtree Therapeutics trades on the NASDAQ under the ticker symbol "WINT."

Who are Windtree Therapeutics' major shareholders?

Windtree Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (1.87%) and Renaissance Technologies LLC (0.80%). Company insiders that own Windtree Therapeutics stock include Craig Fraser, Eric Curtis, James Huang, John P Hamill and Steven Simonson.
View institutional ownership trends for Windtree Therapeutics
.

Which major investors are selling Windtree Therapeutics stock?

WINT stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc..
View insider buying and selling activity for Windtree Therapeutics
or view top insider-selling stocks.

Which major investors are buying Windtree Therapeutics stock?

WINT stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Windtree Therapeutics stock in the last two years include Craig Fraser, Eric Curtis, James Huang, John P Hamill, and Steven Simonson.
View insider buying and selling activity for Windtree Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Windtree Therapeutics?

Shares of WINT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Windtree Therapeutics' stock price today?

One share of WINT stock can currently be purchased for approximately $0.56.

How much money does Windtree Therapeutics make?

Windtree Therapeutics has a market capitalization of $16.44 million and generates $200 thousand in revenue each year. The company earns $-67.64 million in net income (profit) each year or ($2.480010) on an earnings per share basis.

How many employees does Windtree Therapeutics have?

Windtree Therapeutics employs 31 workers across the globe.

What is Windtree Therapeutics' official website?

The official website for Windtree Therapeutics is www.windtreetx.com.

How can I contact Windtree Therapeutics?

Windtree Therapeutics' mailing address is 2600 KELLY ROAD SUITE 100, WARRINGTON PA, 18976. The company can be reached via phone at (215) 488-9300, via email at [email protected], or via fax at 215-488-9301.

This page was last updated on 5/19/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.